Publications by authors named "Alan Wakeling"

Claim this Profile
M
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Suleiman Massarweh, C Kent Osborne, Shou Jiang, Alan E Wakeling, Mothaffar Rimawi

Cancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).
Stephen Hiscox, Liam Morgan, Denise Barrow, Carol Dutkowskil, Alan Wakeling

Clin Exp Metastasis· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
Nicola J Jordan, Julia M W Gee, Denise Barrow, Alan E Wakeling, Robert I Nicholson

Breast Cancer Res Treat· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Jiang Shou, Suleiman Massarweh, C Kent Osborne, Alan E Wakeling, Simale Ali

J Natl Cancer Inst· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.
Seiichi Yano, Kaoru Kondo, Motonori Yamaguchi, Graham Richmond, Michael Hutchison, Alan Wakeling

Anticancer Res· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic potential of tyrosine kinase inhibitors in breast cancer.
Steven Averbuch, Mana Kcenler, Charles Morris, Alan Wakeling

Cancer Invest· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Chunhua Lu, Corey Speers, Yun Zhang, Xiaochun Xu, Jamal Hill, Alan Wakeling

J Natl Cancer Inst· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Iain R Hutcheson, Janice M Knowlden, Tracie-Ann Madden, Denise Barrow, Julia M W Gee, Alan E Wakeling

Breast Cancer Res Treat· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
Janice M Knowlden, Iain R Hutcheson, Helen E Jones, Tracieann Madden, Julia M W Gee, Alan E Wakeling

Endocrinology· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
Alan E Wakeling, Simon P Guy, Jim R Woodburn, Susan E Ashton, Brenda J Curry

Cancer Res· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor.
Andrew P Gilmore, Anthony J Valentijn, Pengbo Wang, Ann M Ranger, Nigel Bundred, Alan Wakeling

J Biol Chem· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor tyrosine kinase inhibitors.
Alan E Wakeling

Curr Opin Pharmacol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
Maureen E Harper, Lindy Goddard, Eve Glynne-Jones, Jean Assender, Carol M Dutkowski, Alan E Wakeling

Prostate· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis